Rhumbline Advisers Genfit S.A. Transaction History
Rhumbline Advisers
- $103 Billion
- Q1 2024
A detailed history of Rhumbline Advisers transactions in Genfit S.A. stock. As of the latest transaction made, Rhumbline Advisers holds 678 shares of GNFT stock, worth $2,447. This represents 0.0% of its overall portfolio holdings.
Number of Shares
678
Previous 678
-0.0%
Holding current value
$2,447
Previous $2,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding GNFT
# of Institutions
7Shares Held
76.8KCall Options Held
0Put Options Held
0-
Israel Englander Millennium Management LLC | New York, Ny29.7KShares$107,2780.0% of portfolio
-
Morgan Stanley New York, NY28.5KShares$102,7550.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il16.8KShares$60,7670.0% of portfolio
-
Optiver Holding B.V. Amsterdam, P7963Shares$3,4760.0% of portfolio
-
Qube Research & Technologies LTD London, X098Shares$3530.0% of portfolio
About Genfit S.A.
- Ticker GNFT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,815,500
- Market Cap $180M
- Description
- Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagno...